Fairmount Funds Management’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-272,498
| Closed | -$10.3M | – | 23 |
|
|
2022
Q3 | $10.3M | Hold |
272,498
| – | – | 1.8% | 19 |
|
|
2022
Q2 | $7.53M | Sell |
272,498
-124,413
| -31% | -$3.44M | 1.72% | 21 |
|
|
2022
Q1 | $21.6M | Buy |
396,911
+104,078
| +36% | +$5.66M | 5.1% | 8 |
|
|
2021
Q4 | $17.1M | Buy |
292,833
+143,500
| +96% | +$8.4M | 5.65% | 8 |
|
|
2021
Q3 | $5.91M | Hold |
149,333
| – | – | 2.15% | 19 |
|
|
2021
Q2 | $6.34M | Buy |
149,333
+40,000
| +37% | +$1.7M | 2.61% | 17 |
|
|
2021
Q1 | $6.73M | Buy |
+109,333
| New | +$6.73M | 2.84% | 17 |
|